Systemic Lupus Erythematosus Outcome Measures for Systemic Lupus Erythematosus Clinical Trials.
BICLA
BILAG
Lupus
Measures
Outcomes
SLEDAI
SRI
Systemic lupus
Journal
Rheumatic diseases clinics of North America
ISSN: 1558-3163
Titre abrégé: Rheum Dis Clin North Am
Pays: United States
ID NLM: 8708093
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
entrez:
3
7
2021
pubmed:
4
7
2021
medline:
29
10
2021
Statut:
ppublish
Résumé
The assessment of systemic lupus erythematosus (SLE) disease activity in clinical trials has been challenging. This is related to the wide spectrum of SLE manifestations and the heterogeneity of the disease trajectory. Currently, composite outcome measures are most commonly used as a primary endpoint while organ-specific measures are often used as secondary outcomes. In this article, we review the outcome measures and endpoints used in most recent clinical trials and explore potential avenues for further development of new measures and the refinement of existing tools.
Identifiants
pubmed: 34215371
pii: S0889-857X(21)00022-3
doi: 10.1016/j.rdc.2021.04.007
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
415-426Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have nothing to disclose.